| A375 | Malignant melanoma skin cancer |
| C. annuum L. | Capsicum annuum Linnaeus |
| CAP | Capsaicin |
| DDs | Drug Delivery Systems |
| DLS | Dynamic Light Scattering |
| DMSO | Dimethyl Sulfoxide |
| DPPC | 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine |
| DSC | Differential Scanning Calorimetry |
| DSPE-PEG2000 | 1, 2-Distearoyl-sn-glycero-3-phosphoethanolamine-NPEG2000 |
| EE | Encapsulation Efficiency |
| EGFR | Epidermal growth factor receptor |
| EMEM | Eagle’s Minimum Essential Medium |
| FBS | Fetal bovine serum |
| FDA | Food and Drug Administration |
| HPLC | High performance liquid chromatography |
| H0 | Null hypothesis |
| Ha | Null hypothesis |
| IC50 | Half maximal inhibitory concentration |
| k562 | Myelogenous leukemia cancer cell line |
| LLOD | Lower limit of Detection |
| LLOQ | Lower limit of Quantitation |
| MCF-7 | Breast cancer cell line, Michigan Cancer Foundation-7 |
| MDA-MB-231 | Triple-negative breast cancer (TNBC) |
| MEM | Minimum Essential Medium |
| MTT | 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium Bromide solution |
| NP | Nanoparticles |
| PBS | Phosphate Buffered Saline |
| PANC1 | Pancreas cancer |
| PDI | Polydispersity Index |
| RPMI | RPMI 1640 growth medium |
| TEM | Transmission Electron Microscopy |
| TRPV1 | The transient receptor potential cation channel subfamily V member 1 |
| Z | Zeta |